Section
This review synthesizes evidence from the DAPT-SHOCK-AMI trial and related studies comparing intravenous cangrelor to crushed oral ticagrelor in AMI complicated by cardiogenic shock, highlighting platelet inhibition efficacy, clinical outco
Hospitalizations, cardiac testing, and revascularizations for chest pain patients without AMI have substantially declined from 2007 to 2021, without an increase in 180-day post-visit AMI risk overall, though older adults show modest rises.
This nationwide Finnish cohort study evaluates the competing risks of stroke, recurrent intracranial bleeding, and mortality with anticoagulation strategies in atrial fibrillation patients who had prior intracranial bleeding. It highlights
The DAPARHT trial demonstrates that dapagliflozin improves kidney function slope over 12 months in heart transplant recipients, offering a promising renal protective strategy without additional safety risks.
Silent atherosclerosis begins early in adulthood, with prevalence and burden increasing with age and differing by sex and vascular territory. Multifactorial determinants including lipids, glycemic markers, inflammation, and lifestyle factor
An international trial found the 0/1-hour high-sensitivity troponin pathway as safe as the standard 0/3-hour approach for ruling out myocardial infarction but observed no significant decrease in emergency department length of stay.
The BioTAK score, a novel biomarker-driven diagnostic tool, accurately discriminates Takotsubo syndrome from acute coronary syndrome pre-angiography, streamlining diagnostic pathways and potentially reducing invasive procedures.
A large UK randomized trial found that routine outpatient CT coronary angiography after ruling out myocardial infarction in suspected acute coronary syndrome did not reduce the risk of subsequent cardiac events compared to standard care.
The ENCIRCLE trial reports sustained mitral regurgitation reduction, improved functional status, and manageable safety outcomes at 2 years after percutaneous transseptal TMVR using the SAPIEN M3 system in high-risk symptomatic MR patients.
This article examines how pulse oximetry may under-detect sleep apnea events in Black individuals due to skin pigmentation-related measurement bias, highlighting heart-rate response as a reliable, pigmentation-independent marker predictive
The SINGLE-CLOSURE trial demonstrated that single-ProGlide closure is noninferior to double-ProGlide closure in reducing vascular complications after transfemoral TAVR, offering a simpler alternative without increased risk.
Plozasiran, targeting APOC3 mRNA, significantly lowers triglyceride levels and reduces acute pancreatitis incidence in severe hypertriglyceridemia patients, according to pooled data from two placebo-controlled trials.
A decade-long multicentre Asian registry analysis revealed no significant difference in all-cause mortality between PCI with drug-eluting stents and CABG for unprotected left main coronary artery disease, highlighting the need for individua
The PREVENT-HF equations demonstrate excellent capability in predicting 10-year risk of heart failure, particularly for HFpEF, across diverse community and clinical samples, highlighting opportunities for subtype-specific risk stratificatio
A pivotal trial demonstrates that coronary CT angiography-guided PCI is noninferior to intravascular ultrasound-guided PCI in reducing target-vessel failure at 12 months, expanding options for personalized coronary intervention guidance.
Long-term treatment with vutrisiran provides sustained improvements in mortality, cardiovascular events, cardiac biomarkers, functional capacity, and quality of life in patients with transthyretin amyloidosis cardiomyopathy, emphasizing the
TAVR significantly reduces death and heart failure events compared to clinical surveillance in patients with moderate aortic stenosis exhibiting at-risk features, marking a potential new therapeutic approach.
This review synthesizes evidence from randomized trials indicating that baseline lipid profiles significantly modify coronary heart disease risk associated with oral menopausal hormone therapy, underscoring the importance of lipid assessmen
This Phase 1b trial demonstrates that oral NLRP3 inhibition with ruvonoflast markedly reduces systemic inflammatory biomarkers in obese individuals at elevated cardiovascular risk, with favorable safety and tolerability, supporting further
This article reviews the SEASON-AR trial demonstrating that TAVR plus medical therapy significantly reduces death, disabling stroke, and heart failure rehospitalization at one year compared to medical therapy alone in high-risk patients wit
